Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

38.49
Delayed Data
As of 4:00pm ET
 -0.70 / -1.79%
Today’s Change
33.60
Today|||52-Week Range
50.40
+0.89%
Year-to-Date
GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
12:03pm / Zacks.com - Paid Partner Content
Biotech Movers: Sarepta, Inovio, Mylan
Jul 20 / TheStreet.com - Paid Partner Content
GSK Stock Falls On Reduced Guidance
Jul 26 / TheStreet.com - Paid Partner Content
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod
Jul 17 / Zacks.com - Paid Partner Content
What Lies in Store for Glaxo (GSK) this Earnings Season?
Jul 20 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co...
Jul 14 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close39.19
Today’s open39.27
Day’s range38.22 - 39.35
Volume3,395,574
Average volume (3 months)5,310,352
Market cap$21.0B
Dividend yield--
Data as of 4:00pm ET, 07/27/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)+5.79%
Earnings growth (next 5 years)+9.51%
Revenue growth (last year)+17.44%
P/E ratio16.6
Price/Sales1.79
Price/Book1.89

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-1.88-2.11%
INCYIncyte Corp-4.47-3.26%
ALXNAlexion Pharmaceutic...+2.85+2.17%
ZTSZoetis Inc-0.05-0.08%
Data as of 4:01pm ET, 07/27/2017

Financials

Next reporting dateAugust 10, 2017
EPS forecast (this quarter)$1.17
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts